The t(14;16) translocation, found in 3%-5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real-world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin <10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7-18.7), the median progression-free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5-2.4) and 4.1 years (95% CI 3.3-5.5), respectively. Worse OS was predicted by age > 60 years (HR = 1.65, 95% CI [1.05-2.58]), as well as revised International Scoring System (R-ISS) 3 (vs R-ISS 2; HR = 2.59, 95% CI [1.59-4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R-ISS 3 predict poor survival.

4th Department of Internal Medicine Hematology University Hospital and Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Complejo Asistencial de Avila Avila Spain

Cota Inc New York New York

Department of Cancer Prevention Medical University of Silesia Katowice Poland

Department of Clinical Oncology Maria Sklodowska Curie National Institute of Oncology Cracow Poland

Department of Experimental Hematology Medical University of Lublin Lublin Poland

Department of Hematology Amyloidosis and Myeloma Unit Hospital Clínic IDIBAPS University of Barcelona Barcelona Spain

Department of Hematology and Stem Cell Transplantation South Pest Central Hospital National Institute of Hematology and Infectology Budapest Hungary

Department of Hematology Blood Neoplasms and Bone Marrow Transplantation Wroclaw Medical University Wroclaw Poland

Department of Hematology Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Toruń Bydgoszcz Poland

Department of Hematology Fundeni Clinical Institute University of Medicine and Pharmacy Carol Davila Bucharest Romania

Department of Hematology Jagiellonian University Medical College Cracow Poland

Department of Hematology Oncology and Internal Diseases Warsaw Medical University Warsaw Poland

Department of Hematology Oncology Medstar Georgetown University Hospital Washington DC

Department of Hematology SPZOZ ZSM in Chorzów Chorzów Poland

Department of Hematology St John's Cancer Center Lublin Poland

Department of Hematology UZ Leuven Leuven Belgium

Department of Infectious and Tropical Diseases Jagiellonian University Medical College Cracow Poland

Department of Internal Medicine 2 University Hospital Würzburg Würzburg Germany

Department of Medicine Queen Mary Hospital University of Hong Kong Pokfulam Hong Kong

Department of Medicine Warren Alpert Medical School Brown University Providence Rhode Island

Division of Hematological Malignancies Dana Farber Cancer Institute Harvard Medical School Boston Massachusetts

Division of Hematology and Medical Oncology Knight Cancer Institute Oregon Health and Science University Portland Oregon

Division of Hematology Oncology Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin

Hematology Department of Medical Science Surgery and Neuroscience University of Siena Siena Italy

Hematology Unit AO Cosenza Cosenza Italy

Hospital Universitario de Salamanca Instituto Biosanitario de Salamanca Salamanca Spain

Institute of Hematology and Transfusion Medicine Warsaw Poland

John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey

Medical University of Lódź Lódź Poland

Tel Aviv Sourasky Medical Center Tel Aviv Israel

The Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York

Weill Cornell Medical College New York New York

Zobrazit více v PubMed

Liu N, Zhou H, Yang G, et al. Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma. Oncol Lett. 2015;9(2):930-936.

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.

Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.

Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204(1):3-12.

Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.

Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol. 2013;97(3):313-323.

Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569-4575.

Avet-Loiseau H, Malard F, Campion L, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117(6):2009-2011.

Narita T, Inagaki A, Kobayashi T, et al. t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer J. 2015;5:e285.

Byun JM, Kim D, Shin DY, Kim I, Koh Y, Yoon SS. Combination of genetic aberration with international staging system classification for stratification of Asian multiple myeloma patients undergoing autologous stem cell transplantation. In Vivo. 2019;33(2):611-619.

Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.

Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630-4634.

Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with ND multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69.

Magarotto V, Bringhen S, Musto P, et al. Doublet vs triplet lenalidomide-containing regimens in newly diagnosed myeloma patients, younger or older than 75 years: subgroup analysis of a phase III study. Blood. 2014;124:2110.

Palumbo A, Gay F, Spencer A, et al. A phase III study of ASCT vs cyclophosphamide- lenalidomide-dexamethasone and lenalidomide- prednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients. Blood. 2013;122:763.

Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895-905.

Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood. 2013;122(8):1376-1383.

Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32(7):634-640.

Larocca A, Cavallo F, Magarotto V, et al. Reduced dose-intensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosphamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of age. Blood. 2013;122:539.

Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946-2955.

Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-2085.

Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589-1596.

Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621-4629.

Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2007;31(6):779-782.

Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140(6):625-634.

Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962.

Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9):2100-2105.

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies